Use of quetiapine in bipolar disorder: A case series with prospective evaluation

T. Suppes; S. L. McElroy; P. E. Keck; L. Altshuler; M. A. Frye; H. Grunze; G. S. Leverich; W. A. Nolen; K. Chisholm; E. B. Dennehy; R. M. Post

doi:10.1097/00004850-200405000-00010

Use of quetiapine in bipolar disorder: A case series with prospective evaluation

T. Suppes, S. L. McElroy, P. E. Keck, L. Altshuler, M. A. Frye, H. Grunze, G. S. Leverich, W. A. Nolen, K. Chisholm, E. B. Dennehy, R. M. Post

Psychiatry and Psychology

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

Original language	English (US)
Pages (from-to)	173-174
Number of pages	2
Journal	International Clinical Psychopharmacology
Volume	19
Issue number	3
DOIs	https://doi.org/10.1097/00004850-200405000-00010
State	Published - May 2004

Keywords

Bipolar disorder
Maintenance
Outpatient
Polypharmacy
Quetiapine
Treatment

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

Access to Document

10.1097/00004850-200405000-00010

Cite this

@article{3e90ad82deda4c5fb0cd5849225f68e7,

title = "Use of quetiapine in bipolar disorder: A case series with prospective evaluation",

abstract = "Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.",

keywords = "Bipolar disorder, Maintenance, Outpatient, Polypharmacy, Quetiapine, Treatment",

author = "T. Suppes and McElroy, {S. L.} and Keck, {P. E.} and L. Altshuler and Frye, {M. A.} and H. Grunze and Leverich, {G. S.} and Nolen, {W. A.} and K. Chisholm and Dennehy, {E. B.} and Post, {R. M.}",

year = "2004",

month = may,

doi = "10.1097/00004850-200405000-00010",

language = "English (US)",

volume = "19",

pages = "173--174",

journal = "International Clinical Psychopharmacology",

issn = "0268-1315",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Use of quetiapine in bipolar disorder

T2 - A case series with prospective evaluation

AU - Suppes, T.

AU - McElroy, S. L.

AU - Keck, P. E.

AU - Altshuler, L.

AU - Frye, M. A.

AU - Grunze, H.

AU - Leverich, G. S.

AU - Nolen, W. A.

AU - Chisholm, K.

AU - Dennehy, E. B.

AU - Post, R. M.

PY - 2004/5

Y1 - 2004/5

N2 - Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

AB - Quetiapine, a new atypical antipsychotic, was added to ongoing treatment of bipolar I outpatients (n=15) for symptoms of illness (mood lability, irritability, psychosis and/ or difficulty sleeping). All evaluations were prospectively obtained, with the majority of patients (n=9) showing much or very much improvement on the Clinical Global Impression for Bipolar Disorder (CGI-BP). Somatic complaints were limited. Mean (SD) duration before changes in medication regimens was 134 (100) days. Studies of the use of quetiapine in maintenance treatment of bipolar disorder are warranted.

KW - Bipolar disorder

KW - Maintenance

KW - Outpatient

KW - Polypharmacy

KW - Quetiapine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=2342512827&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342512827&partnerID=8YFLogxK

U2 - 10.1097/00004850-200405000-00010

DO - 10.1097/00004850-200405000-00010

M3 - Article

C2 - 15107662

AN - SCOPUS:2342512827

SN - 0268-1315

VL - 19

SP - 173

EP - 174

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

IS - 3

ER -

Use of quetiapine in bipolar disorder: A case series with prospective evaluation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this